Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice

Endocrinology

Volumn 154, Issue 9, 2013, Pages 3099-3109

  Camporez, João Paulo G ^a   Jornayvaz, François R ^a,b   Petersen, Max C ^a   Pesta, Dominik ^a   Guigni, Blas A ^a   Serr, Julie ^a   Zhang, Dongyan ^a   Kahn, Mario ^a   Samuel, Varman T ^a   Jurczak, Michael J ^a   Shulman, Gerald I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE 1ALPHA; CERAMIDE; DIACYLGLYCEROL; FIBROBLAST GROWTH FACTOR 21; INSULIN; LIPID; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C ETA; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CONTROLLED STUDY; ENERGY EXPENDITURE; ENZYME ACTIVATION; GLUCOSE HOMEOSTASIS; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; LIPID DIET; LIVER; LIVER CELL; MALE; MOUSE; NONHUMAN; OSMOTIC PUMP; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE, BROWN; ANIMALS; CELLS, CULTURED; DIET, HIGH-FAT; DRUG IMPLANTS; ENERGY METABOLISM; FIBROBLAST GROWTH FACTORS; GLUCOSE INTOLERANCE; HUMANS; INFUSIONS, SUBCUTANEOUS; INSULIN RESISTANCE; ISOENZYMES; LIPECTOMY; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; PROTEIN KINASE C; PROTEIN KINASE C-EPSILON; RECOMBINANT PROTEINS;

EID: 84883167011     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1191     Document Type: Article

References (43)

1. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-131.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346:1221-1231.
3. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51:679-689.
4. Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009;58:250-259.
5. Holland WL, Brozinick JT, Wang LP, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesityinduced insulin resistance. Cell Metab. 2007;5:167-179.
6. Jornayvaz FR, Shulman GI. Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metab. 2012;15:574-584.
7. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106:171-176.
8. Birkenfeld AL, Lee HY, Guebre-Egziabher F, et al. Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice. Cell Metab. 2011;14:184-195.
9. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cells function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
10. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
11. Jornayvaz FR, Birkenfeld AL, Jurczak MJ, et al. Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proc Natl Acad Sci USA. 2011;108:5748-5752.
12. Yu C, Chen Y, Cline GW, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem. 2002;277:50230-50236.
13. Ayala JE, Samuel VT, Morton GJ, et al. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech. 2010;3:525-534.
14. Youn JH, Buchanan TA. Fasting does not impair insulin-stimulated glucose uptake but alters intracellular glucose metabolism in conscious rats. Diabetes. 1993;42:757-763.
15. Lee HY, Birkenfeld AL, Jornayvaz FR, et al. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology. 2011;54:1650-1660.
16. Choi CS, Savage DB, Kulkarni A, et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem. 2007;282:22678-22688.
17. Jornayvaz FR, Jurczak MJ, Lee HY, et al. A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain. Am J Physiol Endocrinol Metab. 2010;299:E808-E815.
18. Camporez JP, Jornayvaz FR, Lee HY, et al. Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistance. Endocrinology. 2013;154:1021-1028.
19. Pesta D, Gnaiger E. High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. Methods Mol Biol. 2012;810:25-58.
20. Tschöp MH, Speakman JR, Arch JR, et al. A guide to analysis of mouse energy metabolism. Nat Methods. 2012;9:57-63.
21. Mu J, Pinkstaff J, Li Z, et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes. 2012;61:505-512.
22. Cantley JL, Yoshimura T, Camporez JP, et al. CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylg- lycerol-mediated hepatic insulin resistance. Proc Natl Acad SciUSA. 2013;110:1869-1874.
23. Lee HY, Choi CS, Birkenfeld AL, et al. Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistance. Cell Metab. 2010;12: 668-674.
24. Choi CS, Befroy DE, Codella R, et al. Paradoxical effects of increased expression of PGC-1α on muscle mitochondrial function and insulin-stimulated muscle glucose metabolism. Proc Natl Acad Sci USA. 2008;105:19926-19931.
25. Jornayvaz FR, Lee HY, Jurczak MJ, et al. Thyroid hormone receptor- α gene knockout mice are protected from diet-induced hepatic insulin resistance. Endocrinology. 2012;153:583-591.
26. Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008;149:6018-6027.
27. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115:1627-1635.
28. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor- 21. Endocrinology. 2007;148:774-781.
29. Berglund ED, Li CY, Bina HA, et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology. 2009;150:4084-4093.
30. Ding X, Boney-Montoya J, Owen BM, et al. Klotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 2012;16:387-393.
31. Adams AC, Cheng CC, Coskun T, Kharitonenkov A. A FGF21 requires βklotho to act in vivo. PloS One. 2012;7:e49977.
32. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care. 2009;32:1542-1546.
33. Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010;53:934-940.
34. Morris-Stiff G, Feldstein AE. Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice. J Hepatol. 2010;53:795-796.
35. Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin- ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013;17:790-797.
36. Lin Z, Tian H, Lam KS, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013;17:779-789.
37. Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 2011;17:55-63.
38. Liu Y, Turdi S, Park T, et al. Adiponectin corrects high-fat dietinduced disturbances in muscle metabolomic profile and wholebody glucose homeostasis. Diabetes. 2013;62:743-752.
39. Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ, Kliewer SA. Inhibition of growth hormone signaling by the fastinginduced hormone FGF21. Cell Metab. 2008;8:77-83.
40. Samuel VT, Beddow SA, Iwasaki T, et al. Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with type 2 diabetes. Proc Natl Acad Sci USA. 2009;106: 12121-12126.
41. Hondares E, Rosell M, Gonzalez FJ, Giralt M, Iglesias R, Villarroya F. Hepatic FGF21 expression is induced at birth via PPARα in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab. 2010;11:206-212.
42. Chau MD, Gao J, Yang Q, Wu Z, Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPKSIRT1- PGC-1α pathway. Proc Natl Acad Sci USA. 2010;107: 12553-12558.
43. Sarruf DA, Thaler JP, Morton GJ, et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes. 2010;59:1817-1824.